Vectored Vaccines for HIV: Status and Path Forward. Rick King International AIDS Vaccine Initiative
|
|
- David Chandler
- 5 years ago
- Views:
Transcription
1 Vectored Vaccines for HIV: Status and Path Forward Rick King International AIDS Vaccine Initiative Thailand 2011
2 Acknowledgements IAVI R&D Chris Parks Wayne Koff Mike Caulfield ld Adrian McDermott Thomas Hassell Pat Fast Thanks for Providing Data Louis Picker David Watkins Dan Barouch Harriett Robinson Gary Nabel Jack Rose Tomas Hanke CAVD Chris Parks/ Nina Russell NIH grant R01-AI
3 Goals for presentation Identify challenges What do we know about efficacy of vectored vaccines and howcanweusetheinformation? we Human trials SIV system Opportunities Incorporating both prevention of infection and control of disease in a vectored vaccine
4 Underlying Challenges of HIV Vaccine Development: Diversity of Epidemic B D Walker, D R Burton Science 2008;320: A vaccine must attack multiple or common targets on HIV
5 Underlying Challenges of HIV Vaccine Development: Chronic Infection and Rapid Mutation Is the game over following escape from the local site of infection?
6 Vectored Vaccines are showing efficacy: Prevention of Infection and Control of Disease X Viral Load Can the next generation of vectored vaccines incorporate both?
7 The best data for improving vectored vaccines will come from clinical trial efficacy results RV144 Thai Trial : Correlates RV 144 Licensure Trial in Thailand RV 144 Phase IIb Efficacy in High Risk Groups DNA + Ad5: Phase IIb Efficacy Ad35/Ad26 Mosaic Platform: Phase IIb Efficacy MVA/Ad26 Mosaic Platform: Phase IIb Efficacy Prevention of infection in RV144 New efficacy data will emerge to guide vector design
8 Improving Vectored Vaccines: Prevention of Infection RV144 and follow up studies will be a rich source of information for vaccine design SIV protection is possible and requires Envelope in vaccine SIV protection mechanisms under investigation Binding antibodies Antibody avidity Neutralizing antibodies CD4 responses
9 Adenovector type 5 prime boost (Ad gag pol nef) No effect on preventing SIV E660 infection Vaccinees (n=8) Controls (n=8) Percen nt Uninfect ted Challenges Provided by David Watkins
10 Ad35 prime Ad26 boost: Protection associated with Env response % Uninfec cted GagPol (N=16) GagPolEnv (N=16) Sham (N=8) Number of IR Challenges Provided by Dan Barouch
11 DNA Prime Ad5 boost: Protection associated with Neutralizing Ab
12 DNA Prime MVA boost: Protection associated with higher avidity Abs nfected Perce ent uni P = Index SIVE66 60 Env Avidity r=0.9 p=< No. of challenges Number of Challenges to Infection
13 Protection from Infection Titered Mucosal Challenge of Rhesus Macaques with SIVmac251 Recapitulates HIV Vaccine Efficacy in Humans G Franchini, P Pegu. M Vaccari, S Gordon, B Keele, M Doster, Y Guan, G Ferrari D Montefiori, D Venzon, C Fenzia, J Lifson, N Michael, J Kim, J Tartaglia AIDS Vaccine 2011
14 Approaches to Improving Protection from Infection Goal: Improve responses to Envelope Identify the nature of protective responses so we can optimize Improve display of native Envelope Improve immunogenicity Prime boost combinations Replicating vectors Combine with protein based vaccine
15 Are vectors delivering most appropriate Env immunogens? Tier 2 Envelope Binds bnabs Does not bind nonneutralizing antibodies RV-144 Proteins Tier 1 Envelope Binds many Abs Common vector delivered Protein gp140
16 Current Env Trials: Few vectors express gp160 Trial OrganizerDeveloper Vaccine VRC 012 (07 I 0167) NIAID, VRC Ad 35 Env gp140 A; Ad 5 Env gp140 A VRC 015 (08 I 0171) NIAID, VRC Ad 5 GagPol B, Env gp140 A/B/C Tiantian vaccinia HIV Vaccine Chinese CDC, Guangxi CDC Replicating Tiantian vaccinia; DNA HIV 1 CN54 gag, pol and env genes HVTN 205/ HVTN 65 GeoVax, HVTN DNA Gag, PR and RT, and Env gp120 and gp41, Tat, Rev, Vpu B; MVA gag pol env truncated gp41 and gp120 B IAVI B001 U. Rochester Medical Center, Ad35 GRIN,Ad35 gp140 IAVI HVTN 073 SAAVI HVNT DNA and MVA prime boost same antigens: Gag RT Tat Nef and truncated gp160 Ad5HVR48.ENVA.01 NIAID Ad 5 Ad48 chimera Env gp140 A HVTN 077 NIAID, HVTN Ad 35 Env gp140 A; Ad 5 gp140 Env A; DNA Env gp140 A HVTN 505; HVTN 204; HVTN NIAID, HVTN DNA Env gp140 A/B/C, gag B, pol B, nef B; Ad 5 GagPol B, Env gp140 A/B/C 082; HVTN 076 HVTN 078 NIAID, EuroVacc, HVTN Pox Env gp120 B, gag pol nef B; Ad 5 Env gp140 A HVTN 083 NIAID, HVTN Ad 35 Env gp140 A; Ad 5 Env gp140 A; Ad 5 Env gp140 B HVTN 084 NIAID, HVTN Ad 5 GagPol lb, Env gp140 A/B/C; Ad 5 gag pol B IAVI B003 IAVI Ad35 gp140a, Ad26 gp140a RV262 NIAID, U.S. Military HIV Research Program (MHRP) DNA Env A, Env C, Env D, Gag; MVA gag pol CM 240, env CM235 E cytoplasmic tail of env truncated HVTN609/VRC HVTN, VRC DNA gag pol nef Env gp140 A/B/C HIVIS 07 Swedish eds Institute tute for Infectious DNA and MVA pkcmvgp160a,,pkcmvgp160b,,pkcmvgp160c Disease Control Ad26.ENVA.01 NIAID Ad 26 Env gp140 A HPTN 027 NIAID, Sanofi Pox Env gp120 BE HVRF Moscow Institute of Protein Env B Immunology, Russian Federation NCHECR AE1 NCHECR, University i of New DNA Gag, RT, Protease, mrnaseh, Rev, Tat, Nef and Env containing i a deletion dl in the middle South Wales 1/3 of the gene; Pox identical seq Gag, Pol, Env, Tat and Rev AE RV 138; B011 WRAIR USMHRP Pox gp120 MN tm/gag/protease LAI Cervico vaginal CN54 St George's, University of London Protein CN54gp140 glycoprotein hsp70 conjugate
17 Can vector design exploit the new discoveries of Env structure and antibody recognition? PGT Abs Provided by Bill Schief
18 Using Conformation dependent antibodies PG9/16 EnvG Hybrid Ti Trimers Env Clade C VSV G tm/ct t VI10 (VSV G) VRC01 PG16 PG9 b12 2F5 Secondary Ab only Cell Surface Staining detected by FACS Maoli Yuan, Aaron Wilson, Kevin Wright, Sanjay Phogat Parks et al (IAVI)
19 Engineering Env to bind most broad neutralizing antibodies Antibodies modified B PG PG VRC VRCPG PGT PGT PGT PGT PGT PGT PGT PGT PGT Denise Wagner Sanjay Phogat Pascal Poignard Burton et al (IAVI)
20 Targeting Functional Env: CDV and VSV based Vectors VSV G Can engineer live replication competent HIV-like vector particles CDV preferentially replicates in lymphoid tissues Functional Env Chris Parks et al (IAVI CAVD) CDV GFP / Ferret abdominal cavity von Messling, Milosevic, Roberto Cattaneo, 2004, PNAS 101:
21 CDV vectors: delivery of cleaved Env to cell surface 1: parental rcdv 2: rcdv SIVEnvΔct4 3: rcdv SIVEnvΔct6 4: rcdv SIVEnvΔct6uncleaved Viral mrna NON-PERMEABILIZED N N P M Env F H VAC L P M F H VAC Env L Chris Parks Jason Zhang et al (IAVI CAVD)
22 CDV vector Tissue targeting and Immunogenicity 1.0E Average Env genome e cps/gram tissue 1.0E E E E+02 10E 1.0E+0000 Peyer's Patch rich intestine Mesenteric Lymph Node Nasal Turbinates Day 1 Day 7 Day 21 Brain Brain Stem Olfactory Bulb OD (450nm m) naive CDV parental CDV SIVEnv Endpoint Titer Chris Parks Gavin Morrow John Coleman et al (IAVI CAVD)
23 Improving Vectored Vaccines: Control of Disease RV144 seems not to reduce viral load Vaccination can control SIV Control of Disease seems not to require Envelope Mechanisms of control are under investigation
24 Ad5 gag,pol,nef (3X): Limited effect on Control of Disease: asma ic mean of py Eq/ml pl Geometr vrna co 10 6 p=0.10 Vaccinees 10 5 Controls p=0.33 p=0.62 p=0.28 p=0.54 p= Weeks after detectable SIVsmE660 infection Provided by David Watkins
25 CMV Vector: Control Associated with CD8 Effecter Memory 6 CD8+ Plasma Vir ral Load Group A (CMV/CMV) 4 n = 6 p = A B C n = Effector (CD28-/CCR7-) 100 A CMV CMV B CMV Ad C DDD Ad 25 0 Group A Group B Group C
26 DNA + IL12 Prime, Ad5 Boost: Control of disease improved by the right prime P=0.002 P= DNA+IL1 EP SIV- 2 rad5 EP SIV-DNA rad5 Naïve Controls Set point Virus Load (>8 weeks)
27 DNA Prime + Boost: Improved by cytokine expression in prime DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) 04) Rashmi Jalah, Barbara Felder, George Pavlakis Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute at Frederick, Frederick, Maryland, USA DNA/Recombinant Modified Vaccinia VirusVaccinated with Simian DNA/Recombinant Modified Vaccinia VirusVaccinated with Simian Immunodeficiency Virus Half of Infected Female Rhesus Macaques Nasally Virus mac251 Viremia to Undetectable Levels in Long-Term Control of Simian Immunodeficiency
28 Approaches to improving Control of Disease Capitalize in information regarding mechanism of control Improve immunogenicity Replicating vectors Prime boost combinations Dealing with diversity Broadening the immune response Focusing on immutable regions
29 Prime boost combinations of vectors Many combinations under test Ad-Ad, Ad-Pox, DNA-vector, Vector-Protein 11 of 22 current clinical trials Avoid antibody responses to the vector Not all combinations are equivalent
30 Rationale for replicating vectors: Attenuated vaccines work Many commonly used vaccines are live attenuated Live attenuated SIV can both prevent infection and control disease
31 Replicating Vectors: Immunogenicity data Replication Competent Pox (Tiantan) Clinical trials underway [China CDC] (NYVAC) Preclinical (Panteleo, CAVD) Measles virus vector- Clinical Trials underway. Key data Safety/Immunogenicity [GSK, NIBSC, St Georges, GentU, I Pasteur] Vesicular stomatitis virus- Clinical Trials to start soon. Key data Safety/Immunogenicity [Profectus HVTN] Sendai virus Advance Preclinical for Mucosal delivery [DNAVEC/IAVI] Cytomegalovirus Preclinical and Research systemic & persistent immunongen expression [OSRU] Replicating Adenovirus- Preclinical & Research [BIDMC, NIH, Panvax] Canine distemper virus Vaccine delivery to lymphoid tissues / mucosal delivery [IAVI CAVD] Vesicular stomatitis virus-hiv chimeras engineered to mimic HIV particles [IAVI CAVD] 31
32 Insert design for improved T-cell responses Concepts are best tested in clinical trial Increase the number of epitopes recognized Mosaic strategy Clinical trial data ~2013 (?) Direct responses to conserved epitopes Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael Mi laj, Hanke T. PLoS One Rolland M, Nickle DC, Mullins JI. PLoS Pathog Dahirel V, Shekhar K, Pereyra F, Miura T, Artyomov M, Talsania S, Allen TM, Altfeld M, Carrington M, Irvine DJ, Walker BD, Chakraborty AK. Proc Natl Acad Sci U S A. 2011
33 HIVcons: preliminary evidence of immunogenicity HIV-CORE002 Healthy, Low-Risk Volunteers in Oxford (Multiple l Prime Boost Combinations under test) t) Screen week 0 week 1 week 2 week 4 week 8 week 9 week 12 week 20 week 28 ChAd MVA Pool 1 Pool 2 Pool 3 Pool 4 Pool 5 Pool 6 FEC Provided by Tomas Hanke, Oxford University
34 Paths forward Vectors can be effective: both protection and control RV144 30% protection Multiple cases of efficacy in SIV low dose challenge Opportunities exist to combine protection from infection and control of disease in a single vaccine Understanding mechanisms of efficacy is important Improved immunogenicity Improved inserts
35
36 Designs for Particle Display of Envelope VSV G Potential for: High density display of gp160 Env & EnvG trimers G + MPER Specific regions (eg mper) Selection of Envelopes with specific properties VSV G-Stem + MPER Chris Parks Ivo Lorenz Caulfield et al (IAVI CAVD NIAID)
37 VSV vector prime replicon boost: Protection associated with antibody responses Neutralizing antibodies to E660 were generated but did not correlate with protection T-cell responses were detected but did p not correlate with protection
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
More informationNovel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012
Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationProfessor Andrew McMichael
BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationHIV/AIDS: vaccines and alternate strategies for treatment and prevention
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Online Meeting Report HIV/AIDS: vaccines and alternate strategies for treatment and prevention Yegor Voronin 1 and Sanjay
More informationThe History of HIV Vaccine Development
The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationOngoing HVTN Trials. Protocol N Trial Collaborators HVTN HVTN VRC DAIDS. Study Product(s)
HVTN 076 17 HVTN DNA multiclade rad5 multiclade 09/2011 The study looks at the immune response of genital and rectal tissues to injections of a DNA vaccine followed by a recombinant adenovirus serotype
More informationCorrelates of Immunity: RV144 - Lessons Learned
Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards
More informationNovel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants
Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities
More informationFUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017
FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical
More informationA global approach to HIV-1 vaccine development
A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed
More informationProgress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
More informationProfessor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationOngoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)
Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;
More informationThe Potential For Harnessing the Immune System to Control HIV
The Potential For Harnessing the Immune System to Control HIV Gordon Dickinson, MD Chief, Infectious Diseases, U Miami School of Medicine, and Co-Director, Special Immunology, Miami VA Medical Center The
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationTrials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
More informationHIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง
HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationImmunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239
Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239 Bin Jia 1, Sharon K. Ng 1, M. Quinn DeGottardi 1, Michael Piatak Jr. 2, Eloísa Yuste
More informationUnderstanding HIV. Transmitted/Founder Viruses. Brandon Keele SAIC-Frederick National Cancer Institute
Understanding HIV Transmission Utilizing Transmitted/Founder Viruses Brandon Keele SAIC-Frederick National Cancer Institute AIDS Vaccine 2011 15 September 2011 Overview Several years ago, the CHAVI sought
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationImmunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239
University of Massachusetts Medical School escholarship@umms Preventive and Behavioral Medicine Publications and Presentations Preventive and Behavioral Medicine 1-23-2009 Immunization with single-cycle
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationStart Date* Sites Description
HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11
More informationHIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationHIV Vaccines: Basic Science
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV Vaccines: Basic Science Richard A. Koup, MD 6 th INTEREST Workshop
More informationBispecific Fusion Antibodies. Exhibit 100% Breadth and Picomolar Potency. Craig Pace, PhD
The Aaron Diamond AIDS Research Center Affiliate of The Rockefeller University Bispecific Fusion Antibodies PG9 Ibalizumab & VRC Ibalizumab Exhibit % Breadth and Picomolar Potency Craig Pace, PhD AIDS
More informationMay HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
More informationHigher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
More informationEDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane
EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9
More informationDevelopment of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
More informationDNA Immunization for HIV Vaccine Development
University of Massachusetts Medical School escholarship@umms GSBS Student Publications Graduate School of Biomedical Sciences 2-25-2014 DNA Immunization for HIV Vaccine Development Yuxin Chen University
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationDevelopment of prophylactic vaccines against HIV-1
Schiffner et al. Retrovirology 2013, 10:72 REVIEW Open Access Development of prophylactic vaccines against HIV-1 Torben Schiffner 1, Quentin J Sattentau 1* and Lucy Dorrell 2,3 Abstract The focus of most
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More informationALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationReplicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.
Replicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.6P Frédéric Tangy Viral Genomics and Vaccination Laboratory Measles
More informationPart One Immunology and Vaccination Strategies for AIDS and TB
Part One Immunology and Vaccination Strategies for AIDS and TB AIDS and Tuberculosis: A Deadly Liaison. Edited by Stefan H.E. Kaufmann and Bruce D. Walker Copyright Ó 2009 WILEY-VCH Verlag GmbH & Co. KGaA,
More informationUSA, Peru, Brazil I 01-I-0079 Completed VRC4302 DNA USA I 04/ Completed APL
Phase Trial D Status Prime Boost 1 Boost 2 Strategy Location HVTN 117 VA Ongoing Ad26.Mos.HV Ad26.Mos4.HV gp140 C Rwanda C89220HPX200 4 Trivalent Vector -, b HVTN 704 AMP Ongoing VRC-HVMAB0 60-00-AB Passive,
More informationHIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
More informationCanadian Immunization Conference 2018 Dec 4
Enveloped Virus-Like Particle (evlp) Cytomegalovirus (CMV) Vaccine is immunogenic and safe: preliminary results of a First-in-Humans Canadian Immunization Network (CIRN) Clinical Trials Network (CTN) -
More informationThe Rational Design of an AIDS Vaccine
Leading Edge Essay The Rational Design of an AIDS Vaccine Daniel C. Douek, 1 Peter D. Kwong, 1 and Gary J. Nabel 1, * 1 Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Building
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationStructural Insights into HIV-1 Neutralization by Broadly Neutralizing Antibodies PG9 and PG16
Structural Insights into HIV-1 Neutralization by Broadly Neutralizing Antibodies PG9 and PG16 Robert Pejchal, Laura M. Walker, Robyn L. Stanfield, Wayne C. Koff, Sanjay K. Phogat, Pascal Poignard, Dennis
More informationIt has been 25 years since HIV-1 was identified as the causative
Vol 4j2 October 8jdoi:.38/nature732 Challenges in the development of an HIV-1 vaccine Dan H. Barouch 1 The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a critically
More informationMedChem 401~ Retroviridae. Retroviridae
MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The
More informationIs an HIV Vaccine Possible?
304 BJID 2009; 13 (August) Is an HIV Vaccine Possible? Nancy A. Wilson 1,2 and David I. Watkins 1,2 1 Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; 2 Wisconsin National
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationHVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
More informationOn an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures
HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm
More informationLong-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018
Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Global HIV Statistics 2017 People living with HIV in 2016 New HIV infections
More informationA Path to an HIV Vaccine: GSID Consortium Activities. Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009
A Path to an HIV Vaccine: GSID Consortium Activities Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009 Project Goals Acquire and disseminate information that will contribute to the
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationSignificant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen
JOURNAL OF VIROLOGY, June 2011, p. 5764 5772 Vol. 85, No. 12 0022-538X/11/$12.00 doi:10.1128/jvi.00342-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Significant Protection
More informationMicro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people
Micro 301 HIV/AIDS Shiu-Lok Hu hus@uw.edu December 3, 2012 Since its discovery 31 years ago Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people In 2011 34.0 million [31.4 35.9 million]
More informationProgress on new vaccine strategies against chronic viral infections
Progress on new vaccine strategies against chronic viral infections Jay A. Berzofsky,, Masaki Terabe, Igor M. Belyakov J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/jci22674. Review Among
More informationStart Date* Sites Description
076 17 083 180 084 100 085 90 098 94 Inovio rad35 clade A clade A rad clade B clade B PENNVAX-GP IL-12 adjuvant September-11 Seattle The study looks at the immune response of genital and rectal tissues
More informationRichard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting
Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pre-exposure prophylaxis (PrEP)
More informationEvaluation of lead HIV-1 vaccine regimen in APPROACH:
Evaluation of lead HIV-1 vaccine regimen in : Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein Hanneke Schuitemaker Martin Freeman,
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationUniversity of Massachusetts Medical School Matthew R. Costa University of Massachusetts Medical School
University of Massachusetts Medical School escholarship@umms GSBS Dissertations and Theses Graduate School of Biomedical Sciences 10-12-2016 FC Receptor-Mediated Activities of Env-Specific Monoclonal Antibodies
More informationAn AIDS vaccine: Why is it so difficult?
An AIDS vaccine: Why is it so difficult? Jaap Goudsmit, MD, PhD Professor of Poverty-related Communicable Diseases, AMC Chairman of the Board CPCD CSO, Crucell Holland BV An AIDS vaccine: Why is it so
More informationT cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces
JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationPRACTICE POINTS AIDS Vaccine 2001: Looking to the Future
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future 1 Ronald T. Mitsuyasu 1 Associate Professor of Medicine, University of California Los Angeles, and Director of the UCLA CARE Center, UCLA Medical
More informationHIV-1 Vaccine Development: Recent Advances in the CTL Platform Spotty Business ACCEPTED
JVI Accepts, published online ahead of print on 7 November 2007 J. Virol. doi:10.1128/jvi.01634-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationIsolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient
Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient Amanda Fabra García, Carolina Beltrán Pavez, Alberto Merino Mansilla, Cristina Xufré, Isabel
More informationSupplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants
Supplementary information Early development of broad neutralizing antibodies in HIV-1 infected infants Leslie Goo, Vrasha Chohan, Ruth Nduati, Julie Overbaugh Supplementary Figure 1. Neutralization profile
More informationLong-Acting Antibodies and Drugs as HIV Prevention Agents. David D. Ho, M.D.
Long-Acting Antibodies and Drugs as HIV Prevention Agents David D. Ho, M.D. the The HIV/AIDS pandemic rages on Key statistics from UNAIDS: 35M dead; 35M living with HIV 2.3M new infections a year or 6,300
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationWe are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%
We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries
More informationInduction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination M. Juliana McElrath 1, * and Barton F. Haynes 2, * 1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research
More informationPotential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion
Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced
More informationTrial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017
Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus
More informationStrategies for an HIV vaccine
Strategies for an HIV vaccine Norman L. Letvin J Clin Invest. 2002;110(1):15-27. https://doi.org/10.1172/jci15985. Perspective The development of an HIV vaccine poses an unprecedented challenge to the
More informationRetroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.
Retroviruses ---The name retrovirus comes from the enzyme, reverse transcriptase. ---Reverse transcriptase (RT) converts the RNA genome present in the virus particle into DNA. ---RT discovered in 1970.
More informationCharacterization of Envelope-Specific Antibody Response Elicited by HIV-1 Vaccines: A Dissertation
University of Massachusetts Medical School escholarship@umms GSBS Dissertations and Theses Graduate School of Biomedical Sciences 1-6-2015 Characterization of Envelope-Specific Antibody Response Elicited
More informationLynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
More informationThird Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program
Third Env Manufacturing Workshop July 20 21, 2017 July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Presentation Outline Importance and Impact of an HIV Vaccine DAIDS/VRP Programmatic
More informationDevelopment of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationNIH Public Access Author Manuscript Nat Rev Microbiol. Author manuscript; available in PMC 2014 November 19.
NIH Public Access Author Manuscript Published in final edited form as: Nat Rev Microbiol. 2014 November ; 12(11): 765 771. doi:10.1038/nrmicro3360. Novel vaccine vectors for HIV-1 Dan H. Barouch and Center
More informationImmunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial
Immunogenicity of ALVAC HIV (vcp1521) and AIDSVAX B/E Prime Boost Vaccination in RV144, Thai Phase III HIV Vaccine Trial M. de Souza, R. Trichavaroj, A. Schuetz, W. Chuenarom, Y. Phuang ngern, S. Jongrakthaitae,
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationNIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Nature. 2009 January 1; 457(7225): 87 91. doi:10.1038/nature07469. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in
More information